Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia

NCT07146022 is registered in ClinicalTrials.gov with Veradermics, Inc. as lead sponsor.

NCT NCT07146022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07146022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia
Lead sponsor
Veradermics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 25, 2025
Completion date
January 31, 2028
Enrollment
552 (estimated)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

aga, androgenetic alopecia, androgenetic alopecia (aga), female androgenetic alopecia, hair loss